WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT
|
|
- Irma Burke
- 5 years ago
- Views:
Transcription
1 WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT Thursday, October 25, 2018 Sarah Sungurlu DO Assistant Professor Division of Pulmonary and Critical Care Medicine
2 Disclosures I have no actual or potential conflict of interest in relation to this program/presentation. I will not be discussing off-label uses of any medications
3 Objectives Relate diagnostic criteria for COPD to improve patient and provider awareness of the disease Discuss available maintenance therapy for COPD that can be instituted in the ED setting Appraise the literature supporting and refuting vaccinations Prioritize the importance of proper medication use and smoking cessation in the overall management plan of the COPD patient.
4 Chronic Obstructive Pulmonary Disease Global strategy for chronic Obstructive Lung Disease (GOLD) definition: Preventable and Treatable disease with extrapulmonary effects and a pulmonary component characterized by airflow obstruction that is no longer fully reversible and is usually progressive and associated with abnormal inflammatory response of lung to noxious particles or gases 1. Pauwels et al. Am J Respir Crit Care Med. 2001, 163:
5 Pathophysiology Chronic productive cough for at least 3 consecutive months in 2 consecutive years (driven by chronic inflammation) Abnormal enlargement of airways distal to terminal bronchioles due to destruction of their walls without obvious fibrosis
6 Remodeling: mucus hypersecretion, bronchiolar edema, smooth muscle hypertrophy and peribronchiolar fibrosis result in narrowing of small airways Barnes. NEJM. 2000, 343:
7 Epidemiology COPD 3 rd leading cause of death in America 5 th most common worldwide 3 million deaths worldwide from COPD in NHANESIII data (US survey ): Prevalence of 14% in US adults aged when using the GOLD criteria of fixed ratio post-bronchodilator spirometry 2 More than 50% patients with low PFTs were unaware of COPD 1. CDC and WHO 2. Tilert et al. Respiratory Research. 2013, 14:103
8 Burden of disease In 2010 the United States spent 50 billion dollars on COPD 1 The costs associated with hospitalization accounts for more than 70% of this spending 2 1. Guarascio et al. Clinicoecom Outcomes Res. 2013; 5: Sullivan et al. Chest (2 Suppl): 5S-9S
9 Factors predicting readmission Lower socio-economic status Extremes of BMI Comorbidities It is important to remember that a major predictor for future exacerbations is previous exacerbations 1. Kumbhare et al. Chronic Obstr Pulm Dis. 2016; 3(2):
10 Many risk factors lead to COPD COPD 1. Eisner et al. Am J Respir Crit Care Med. 2010, 182:
11 Diagnostic Criteria for COPD- Spirometry GOLD Criteria: Spirometry with post bronchodilator FEV1/FVC <0.70 ATS and ERS Criteria: Fixed ratio cutoff can lead to misdiagnosis of >20% of patients Use of LLN cutoff (equal to the 5 th percentile) based on NHANES III data for age, ethnicity, gender and height
12 Recognizing COPD in the Emergency Department Previous diagnosis of COPD Recognize that many patients have been clinically diagnosed without spirometry and therefore only have presumed COPD Should be encouraged to follow-up with primary care physician or pulmonologist to confirm diagnosis or rule out other causes with pulmonary function tests
13 Recognizing COPD in the Emergency Department, continued Emphysema on previous imaging Chronic bronchitis historical description Smoking history Age >55 Wheezing 1. Radeos et al. Am J Emerg Med. 2009; 27(2)191-6
14 Differential Diagnosis of COPD Diagnosis COPD Asthma Congestive Heart Failure Bronchiectasis Others Suggestive Features Mid life onset Slowly progressive symptoms History of exposure or risk factor Earlier onset (though can develop in adult) Widely variable symptoms day to day Diurnal symptoms (worse at night/early morning) Allergy, rhinitis, eczema Family history Chest X-ray shows dilated heart and pulmonary edema (cardiac asthma) Pulmonary function tests show restriction not obstruction Large volumes of purulent sputum Colonized with bacteria Chest X-ray and/or CT differentiate Tuberculosis, bronchiolitis obliterans, diffuse panbronchiolitis, lymphagioleiomyotasis, etc.
15 Severity of Symptoms Grade 0 Description of breathlessness I only get breathless with strenuous exercise 1 I get short of breath when hurrying on level ground or walking up a slight hill On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace I stop for breath after walking about 100 yards or after a few minutes on level ground I am too breathless to leave the house or I am breathless when dressing
16 Severity of COPD GOLD 2017 ATS severity of obstruction: Mild >60% Moderate 30-60% Severe <30% GOLD 1 GOLD 3-4 C D 2 or 1 hospitalization GOLD 1-2 A B 1 or no hospitalization mmrc <2 or CAT <10 FEV1 (% predicted) 80 GOLD GOLD GOLD 4 <30 mmrc 2 or CAT 10 GOLD or 1 hospitalization 1 or no hospitalization C A mmrc <2 or CAT <10 D B mmrc 2 or CAT 10
17 Inhalers at a Glance
18 Acute exacerbation of COPD (AECOPD) An event in the natural course of the disease characterized by a change in baseline dyspnea, cough and sputum beyond normal day variations, with an acute onset, which may warrant a change in medication Initial therapies Oxygen, inhaled bronchodilators, systemic corticosteroids Early NIV has improved outcomes (over invasive ventilation with a success rate of 80-85%)
19 Treatment of AECOPD, steroids Steroids do shorten recovery, treatment failure, and reduce risk of early relapse Preferred dosing is prednisone 40mg for 5-7 days REDUCE trial: shorter course of systemic steroids yields equal length to next exacerbation Oral prednisone is equally effective to intravenous administration if oral access is available and intact.
20 Treatment of AECOPD, antibiotics Controversial, but some evidence of benefit with antibiotics in absence of pneumonia To reduce overexposure to antibiotics suggest use of antibiotics if have increase in dyspnea, sputum volume and sputum purulence Duration 5-7 days Choice should be based on local resistance pattern (macrolide, tetracycline)
21 Bronchodilators Increase FEV1, improve exercise performance, reduce dynamic hyperinflation Beta 2 agonists SABA (albuterol) LABA (formoterol, salmeterol ) Methylxanthines Theophylline Limited and contradictory evidence, risk of toxicity 1. Vogelmeier et al. Am J Respir Crit Care Med. 2017, 195:
22 Bronchodilators Antimuscarinics SAMA (ipratropium) Slightly greater effect on lung function, health status, requirement for oral steroids over SABA 1 LAMA (tiotropium, aclidinium ) Greater effect on exacerbation rates than LABA 2 1. Appleton et al. Cochrane Database Syst Rev. 2006, (3):Cd Vogelmeier et al. NEJM. 2011, 364:
23 Combination Bronchodilators Combination of SABA/SAMA Improve FEV1 and symptoms compared to monotherapy (level A) Combination LABA/LAMA Improve FEV1 and reduce symptoms compared to monotherapy (level A) Reduce exacerbation compared with monotherapy or combination of ICS/LABA (level B) FLAME trial: 1 11% reduction in annual exacerbation rate in LAMA/LABA compared to ICS/LABA group Increased risk for pneumonia in ICS/LABA group- 4.8% vs 3.2% 1. Wedzicha et al. NEJM. 2016, 374:
24 Anti-inflammatory Agents Reduce number of exacerbations Inhaled Corticosteroids ICS/LABA is more effective than either drug as monotherapy in improving lung function and reducing exacerbations in moderate to severe COPD (level A) TORCH trial 1 : In patients with FEV1<50% use of ICS/LABA decreases annual rate of exacerbation but not mortality Triple inhaled therapy ICS/LAMA/LABA improves lung function, symptoms and health status (level A) and reduces exacerbations (level B) compared to ICS/LABA or LAMA monotherapy Oral glucocorticoids No role in chronic daily treatment with numerous side effects (level A) and no evidence of benefits (level C) 1. Calverley et al. NEJM. 2007, 356: Vogelmeier et al. Am J Respir Crit Care Med. 2017, 195:
25 DPI MDI SMI Inhalers at a Glance
26 Other considerations in choice of inhaler Arthritis of the hands/fingers Avoid metered dose inhalers (try dry powder breath actuated inhalers or nebulizers) Poor technique Spacers, breath actuated dry powder, or nebulizer Poor memory Simplify regimen, limit dose frequency Income Think about costs of drugs (Insurance formulary)
27 Education on proper use of medications Individualized and guided based on severity of symptoms risk of exacerbations side-effects comorbidities drug availability and cost and the patient's response, preference and ability to use various drug delivery devices Assess inhaler technique every visit with instruction and demonstration
28 Anti-inflammatory Agents, continued Phosphodiesterase 4 inhibitors (Roflumilast) Reduction in exacerbation if on LABA/ICS (level B) Chronic bronchitis, >1 exacerbation in last year, FEV1 <50% Side effects: diarrhea, nausea, reduced appetite, weight loss, abdominal pain, headache Antibiotics Azithromycin 250 or 500 three times per week reduces risk of exacerbations (level A) Azithromycin does increase incidence of bacterial resistance (level A) and hearing impairment (level B) QTc prolongation and sudden cardiac death 3 1. Martinez et al. Lancet. 2015, 385: Vogelmeier et al. Am J Respir Crit Care Med. 2017, 195: Albert et al. NEJM. 2011, 365:
29 COPD discharge care bundles 1. Hopkinson et al. Thorax. 2012; 67:90-92
30 Natural history of lung function decline in smoker versus nonsmoker Nonsmoker healthy lungs lose 20-30mL/year of FEV1 after age 35 and rate of decline starts to accelerate with aging Smoking accelerates the rate of decline (on average 15ml/year larger) 1 As does COPD exacerbations 1. Kertsjens et al. Thorax. 1997;52:
31 Strategies to encourage smoking cessation Ask: every patient at every visit smoking status Advise: strongly encourage quitting Assess: willingness and rationale to quit Assist: quit plan, counselling, social support, pharmacotherapy, supplemental materials Arrange: follow-up contact in person or via telephone Things to discuss: Tie tobacco to current health, social and economic costs and the impact of smoking on children and others in home Identify potential consequences (infertility, heart attacks, strokes, gum disease, lung cancer, children increased risk of SIDS and respiratory infections, etc.) Identify benefits they believe they derive from smoking and find alternative methods to fill these voids after cessation Identify their barriers (partner or coworkers who smoke etc.) 1. Vogelmeier et al. Am J Respir Crit Care Med. 2017;195(5):
32 Pharmacotherapy Varenicline (Chantix) $450 Start with 0.5mg QD for 3 days then 0.5mg BID for four days, then 1mg BID for total 12 weeks Adjust dose for renal function Neuropsychiatric symptoms (unusual dreams, insomnia, agitation, depression, suicide) Bupropion SR (Zyban) $ mg SR QD for 3 days then 150mg SR BID Insomnia, dry mouth, SEIZURES, monitor for mood changes including suicidality Both increase long term quit rates but should be used as a component of supportive intervention program rather than sole intervention for smoking cessation. Nicotine Replacement Therapy Various forms increases longterm abstinence rate and is more effective than placebo Effectiveness and safety of e-cigarettes is uncertain at present
33 NRT Cost Dose Duration Directions Adverse Transdermal $58-80/24 patches 21, 14, 5mg/24 hr 8 week Can supplement with gum Skin reactions, sleep disturbances Lozenge $40/72 count 2 or 4mg 12 weeks Allow to dissolve, no drinking 15 min Gum $26-40/100 sticks 2 or 4mg 2-3 months Chew and then park between cheek and gum HA, diarrhea, nausea Jaw fatigue, belching, nausea Nasal $193/10mL bottle 1mg per nostril 2-3 months Spray technique Nasal irritation, rhinorrhea Inhaler $194/cartridge 80 puffs=1mg, requires 3-4 puffs/minute for 20-30min use Q1 PRN 2-3 months Puff more frequently then cigarrettes Cough, mouth/throat irritation. Avoid if RAD
34 Pulmonary rehabilitation A program of education and exercise designed to manage respiratory illness Sessions supervised by PT, RT, Pulmonologist, nutritionist Specifically designed for patient to the level they can handle Both strength and endurance training Most programs meet 2 times a week and last generally 8 weeks Medicare Part B covers pulmonary rehabilitation services for Moderate to Very Severe COPD as defined by GOLD Classification Improves symptoms, QOL, and physical and emotional participation in everyday activities
35 Outpatient follow-up Indicated within 1-4 weeks after acute exacerbation Review understanding of treatment regimen, inhaler technique Reassess oxygen needs PFTs are recommended at 8-12 weeks of discharge (baseline conditions) to establish diagnosis Can have significant improvement in FEV1 >8weeks after acute exacerbation Can consider acute spirometry in hospitalized patient or shortly after discharge to try to reduce overdiagnosis
36 Vaccinations Influenza Reduce serious illnesses such as LRTI and death, significant reduction in total number of exacerbations 1 Killed or live inactivated forms Pneumococcal PCV 13 and PCV valent pneumococcal polysaccharide vaccine (PPSV23) reduce the incidence of community acquired pneumonia in COPD patients <65 with an FEV1 <40% predicted and in those with comorbidities including chronic heart or lung disease General population of adults >65 years the 13 valent conjugated pneumococcal vaccine (PCV13) has demonstrated significant efficacy in reducing bacteremia and serious invasive pneumococcal disease 1. Criner et al. Chest. 2015;147(4):
37 Other cost effective interventions: Improving ventilation in areas where indoor cooking/heating takes place Hygiene Nutrition Prevention of infection.
38 Palliative care Relief of dyspnea, pain, anxiety, depression, fatigue, and poor nutrition along with advance care planning
39 Resources For patients: For providers: ATS/ERS guidelines GOLD guidelines
40
COPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCOPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic
COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic Learning Objectives Know the adverse effects of COPD exacerbations Know mainstays
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationCLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease
CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationBlue, Pink and everything in between: an update on COPD. Tara Lohmann MD FRCPC Division of Respirology University of Calgary
Blue, Pink and everything in between: an update on COPD Tara Lohmann MD FRCPC Division of Respirology University of Calgary Disclosures I have eaten lunches provided by many pharmaceutical companies (GSK,
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX COPD OUTLINE Definition and Overview Pathophysiology Diagnosis and Assessment Therapeutic
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationWhat is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018
What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationCOPD. Stan Kellar, MD. Physiology 11/4/2014. Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine
Stan Kellar, MD Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine COPD Physiology The lungs are filters Filter in oxygen Filter out carbon dioxide (Vascular filter, not part of this discussion)
More informationAssessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)
William P. Saliski Jr. DO Montgomery Pulmonary Consultants Management of Stable COPD Pharmacotherapy Oxygen Smoking Cessation Vaccinations Rehabilitation Surgery Future Discussions Assessing Severity Staging
More informationPeople with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.
COPD Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More informationChronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Catherine Whittaker (BPharm, MRPharmS) Abstract Chronic Obstructive Pulmonary Disease affects millions of people, has a major impact on quality of life and has become
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 9 PURPOSE To assure that DOP inmates with Pulmonary Diseases are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers and Chronic Disease Nurses are
More informationIMPORTANT POINTS ABOUT MEDICATIONS
IMPORTANT POINTS ABOUT MEDICATIONS The U.S. Food & Drug Administration (FDA) advises that there are significant health benefits to quitting smoking. The health benefits of quitting smoking include a reduction
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationSTOP SMOKING with Nicotine Replacement Therapy
STOP SMOKING with Nicotine Replacement Therapy Gita Anjali Shah, Clinical Pharmacist, UK and Guest Lecturer, Faculty of Pharmacy, Mahidol University Shocking Statistics According to the last Global Adult
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationAmerican Thoracic Society (ATS) Perspective
National Surveillance System for Chronic Lung Disease (CLD): American Thoracic Society (ATS) Perspective Gerard J. Criner, M.D. Chronic Obstructive Pulmonary Disease (COPD) l Definition: Group of chronic
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More information